122 related articles for article (PubMed ID: 30682105)
81. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
[TBL] [Abstract][Full Text] [Related]
82. Accumulation of exhausted CD8+ T cells in extramammary Paget's disease.
Iga N; Otsuka A; Yamamoto Y; Nakashima C; Honda T; Kitoh A; Nakajima S; Egawa G; Nomura T; Dainichi T; Matsushita S; Tanizaki H; Yamamoto Y; Funakoshi T; Fujisawa Y; Fujimura T; Hata H; Ishida Y; Kabashima K
PLoS One; 2019; 14(1):e0211135. PubMed ID: 30682105
[TBL] [Abstract][Full Text] [Related]
83. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H
Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816
[TBL] [Abstract][Full Text] [Related]
84. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
85. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
86. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
87. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
88. A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors.
Ohara K; Fujisawa Y; Yoshino K; Kiyohara Y; Kadono T; Murata Y; Uhara H; Hatta N; Uchi H; Matsushita S; Takenouchi T; Hayashi T; Yoshimura K; Fujimoto M
J Dermatol Sci; 2016 Sep; 83(3):234-9. PubMed ID: 27329007
[TBL] [Abstract][Full Text] [Related]
89. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
90. Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Moon YW; Hajjar J; Hwu P; Naing A
J Immunother Cancer; 2015; 3():51. PubMed ID: 26674411
[TBL] [Abstract][Full Text] [Related]
91. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease.
Yoshino K; Fujisawa Y; Kiyohara Y; Kadono T; Murata Y; Uhara H; Hatta N; Uchi H; Matsushita S; Takenouchi T; Hayashi T; Ohara K
J Dermatol; 2016 Jun; 43(6):633-7. PubMed ID: 26603144
[TBL] [Abstract][Full Text] [Related]
92. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H; Paz-Ares L; Horn L; Spigel DR; Steins M; Ready NE; Chow LQ; Vokes EE; Felip E; Holgado E; Barlesi F; Kohlhäufl M; Arrieta O; Burgio MA; Fayette J; Lena H; Poddubskaya E; Gerber DE; Gettinger SN; Rudin CM; Rizvi N; Crinò L; Blumenschein GR; Antonia SJ; Dorange C; Harbison CT; Graf Finckenstein F; Brahmer JR
N Engl J Med; 2015 Oct; 373(17):1627-39. PubMed ID: 26412456
[TBL] [Abstract][Full Text] [Related]
93. Perforin and granzymes: function, dysfunction and human pathology.
Voskoboinik I; Whisstock JC; Trapani JA
Nat Rev Immunol; 2015 Jun; 15(6):388-400. PubMed ID: 25998963
[TBL] [Abstract][Full Text] [Related]
94. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS; Soria JC; Kowanetz M; Fine GD; Hamid O; Gordon MS; Sosman JA; McDermott DF; Powderly JD; Gettinger SN; Kohrt HE; Horn L; Lawrence DP; Rost S; Leabman M; Xiao Y; Mokatrin A; Koeppen H; Hegde PS; Mellman I; Chen DS; Hodi FS
Nature; 2014 Nov; 515(7528):563-7. PubMed ID: 25428504
[TBL] [Abstract][Full Text] [Related]
95. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
